Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

History

Nasal Septal Perforati

Oh, Changhoon

Phase II study of the

TRPV Cation Channels

See All (4) pages

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.

Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Antineoplastic Agents
Endometrial Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Protein Kinase Inhibitors
Quinoxalines
Sulfonamides

authors with profiles

Michael Birrer